Women's Health has profiled three registered dietitians who take GLP-1 medications themselves and have decided to say so publicly, in a field where admitting it invites accusations of professional failure. The piece is built on their accounts, not on new data, and it is a useful window into how the drugs are actually discussed by people who prescribe nutrition for a living.

GLP-1 receptor agonists are the drug class that includes semaglutide and tirzepatide, originally developed for type 2 diabetes and now widely used for obesity. Women's Health reports that 12 percent of Americans are taking one, which makes the secrecy around them more striking than the use.

Why dietitians catch extra heat

Gianna Beasley, 29, a Denver dietitian, told the magazine she has heard clients ask why they would work with a dietitian who is not in great shape herself. Her answer is that her education and expertise have nothing to do with the size or shape of her body, which is a sharper line than most of the industry manages.

Whitney Black, 32, in Omaha, described worrying that people would think she was a fraud before she spoke with her endocrinologist and started a medication. Summer Kessel, 39, in Tampa, said she once believed becoming a dietitian would let her manage her weight, and that it never worked because the problem was biology, not a knowledge deficit.

What they actually reported

Beasley says her joint pain, brain fog and swelling are gone, she sleeps better, and her PMOS symptoms came under control after starting treatment. Black says her hunger and fullness cues normalized once she adjusted, describing it as a night and day difference.

Side effects are not skipped over. Beasley says nausea and fatigue nearly made her quit in the first three months and cleared by month four, and Black says she snacked through the day at first because her appetite had collapsed.

Where the evidence stops

This is three interviews, not a study, and the article presents it as such. Beasley's list of wider possible uses, from cardiovascular risk to migraine severity, is described in the piece as links rather than established outcomes, and none of it is quantified.

Bottom line

The interesting claim here is not clinical, it is cultural: that obesity is treated as a character flaw in a way high blood pressure is not. Whether going public changes that is the question the piece leaves open.